Abstract
Aims Individuals with type 1 diabetes (T1D) carry a markedly increased risk of stroke, with distinct clinical and neuroimaging characteristics as compared to those without diabetes. Using whole-genome sequencing (WGS) and whole-exome sequencing (WES), we aimed to find rare and low-frequency genomic variants associated with stroke in T1D. The lead findings were followed up in various datasets to replicate the findings and to assess their specificity to diabetes.
Methods and Results We studied stroke genetics in 1,051 individuals with T1D using WGS or WES. We analysed the genome with single-variant analyses, gene aggregate analyses, and aggregate analyses on genomic windows, enhancers and promoters. Furthermore, we attempted replication in T1D using a genome-wide association study (N=3,945) and direct genotyping (N=3,600), and in the general population from the FinnGen project and UK Biobank summary statistics. We identified a rare missense mutation on SREBF1 associated with hemorrhagic stroke (rs114001633, p.Pro227Leu, p-value=8.96×10-9), which further replicated in T1D. Using gene aggregate analysis with protein altering or protein truncating variants, we identified exome-wide significant genes: ANK1 and LRRN1 displayed replication evidence in T1D, while LRRN1, HAS1 and UACA replicated in the general population (UK Biobank). Furthermore, we performed sliding-window analyses and identified 14 genome-wide significant windows for stroke on 4q33-34.1, of which two replicated in T1D, and a suggestive genomic window on LINC01500, which replicated in T1D. Finally, with the regulatory region aggregate analyses, we identified a stroke-associated TRPM2-AS promoter (p-value=5.78×10-6), which we validated with an in vitro cell-based assay. TRPM2 has been previously linked to ischemic stroke.
Conclusions Here, we report the first genome-wide analysis on stroke in individuals with diabetes. We identified multiple stroke risk loci with evidence of replication: 4q33-34.1, SREBF1, and ANK1 for stroke in T1D; and HAS1, UACA, LRRN1, LINC01500, and TRPM2-AS promoter for stroke potentially generalizable to the non-diabetic population.
Competing Interest Statement
P-H G has received investigator-initiated research grants from Eli Lilly and Roche, is an advisory board member for AbbVie, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Cebix, Eli Lilly, Janssen, Medscape, Merck Sharp & Dohme, Mundipharma, Nestle, Novartis, Novo Nordisk and Sanofi; and has received lecture fees from AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Elo Water, Genzyme, Merck Sharp & Dohme, Medscape, Novartis, Novo Nordisk, PeerVoice, Sanofi, and Sciarc. Other authors declare no competing interests.
Funding Statement
This work was supported by grants from Folkhalsan Research Foundation; Wilhelm and Else Stockmann Foundation; 'Liv och Halsa' Society; Sigrid Juselius Foundation (220027); Helsinki University Central Hospital Research Funds [TYH2018207]; Novo Nordisk Foundation [NNF OC0013659], Academy of Finland [299200 and 316664]; European Foundation for the Study of Diabetes (EFSD) Young Investigator Research Award funds; an EFSD award supported by EFSD/Sanofi European Diabetes Research Programme in Macrovascular Complications; Finnish Foundation for Cardiovascular Research; Sigrid Juselius foundation (220027); and the Finnish Diabetes Research Foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of the Helsinki and Uusimaa Hospital District (491/E5/2006, 238/13/03/00/2015, and HUS-3313-2018) gave ethical approval for the study protocol, and we performed the study in accordance with the Declaration of Helsinki. All participants gave informed consent before participation.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Manuscript has been re-formatted.
Data Availability
Gene aggregate test stroke summary statistics are provided in the Supplementary Data. The sequencing data supporting the current study cannot be deposited in a public repository because of restrictions due to the study consent. The Readers may propose collaboration to research the individual level data with correspondence with the lead investigator.
